Vascular Stent Market 2020 New Innovations, Technology Progress- Abbott Laboratories, Boston Scientific Corporation

0 Comments

The MarketWatch News Department was not involved in the creation of this content.

Global Vascular Stent Market

Sep 29, 2020 (Market Insight Reports) —
Vascular Stent Industry 2020 global market research report analyzes the market status, share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis. Vascular Stent industry breakdown the data by region, manufacturers, type and application.

The potential of Vascular Stent market and provides statistics and information on market size, shares, market attractiveness and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities. Additionally, the report also highlights market entry strategies for various companies.

Request a Sample Report:

https://www.marketinsightsreports.com/reports/04272008139/global-vascular-stent-market-analysis-by-type-coronary-peripheral-technology-bare-metal-drug-eluting-bio-resorbable-mode-of-delivery-end-user-by-region-by-country-2019-edition-opportunities-and-forecast-2014-2024-by-mode-of-delivery-self-expandable-drug-eluting-expandable-by-end-user-hospital-ambulatory-surgical-centre-by-region-north-america-europe-asia-pacific-row-and-by-country-u-s-canada-u-k-germany-france-italy-china-japan-india-brazil/inquiry?source=MW&Mode=NG23

Company Analysis – Abbott Laboratories, Boston Scientific Corporation, Cardinal Health, Medtronic, Terumo Corporation, B. Braun Melsungen, W.L. Gore & Associates, Cook Medical, Biotronik, Meril LifeSciences.

Latest News and Developments

Oct. 30, 2017: ABBOTT PARK, Ill. Abbott (NYSE: ABT) today announced it received CE Mark for XIENCE Sierra, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system. CE Mark allows sale of the device in the European Union and other countries that recognize CE Mark. Advances in this generation of XIENCE — which is known for its exceptional safety — include new features that make it easier for cardiologists to successfully complete complex procedures that now account for up to 70 percent of cases.2

Oct. 16: NATICK, Mass, — Boston Scientific Corporation (NYSE: BSX) announced today that the PROMU Everolimus-Eluting Coronary Stent System has received CE Mark approval, making Boston Scientific the only company to offer two distinct approved drug-eluting stent (DES) platforms in the CE geographies. This